Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. Show More...

  • Website https://www.corcept.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 67.60 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.38 -0.39 -0.41 -0.46 -0.31 -0.06 0.07 1.04 0.6 0.77 0.87
    Dividends USD
    Payout Ratio % *
    Shares Mil 68.0 83.0 93.0 100.0 101.0 107.0 116.0 125.0 127.0 123.0 122.0
    Book Value Per Share * EUR 0.35 0.4 0.54 0.22 -0.010 0.11 0.26 0.63 1.97 2.61 3.28
    Free Cash Flow Per Share * EUR -0.25 -0.24 -0.29 -0.28 -0.28 -0.02 0.15 0.28 0.82 0.79
    Return on Assets % -104.67 -99.65 -54.75 -56.72 -64.24 -14.8 13.49 89.27 28.34 26.02 27.68
    Financial Leverage (Average) 1.18 1.14 1.61 3.0 2.81 1.66 1.15 1.13 1.11 1.09
    Return on Equity % -119.84 -115.44 -78.79 -111.15 -356.04 -84.82 27.19 111.15 32.31 29.11 30.48
    Return on Invested Capital % -119.84 -115.44 -71.2 -91.01 -168.43 -17.43 20.92 111.17 31.37 27.55 29.01
    Interest Coverage -20.42 -9.19 -7.34 -1.16 4.99
    Current Ratio 6.48 7.91 11.37 4.58 2.23 2.35 2.4 4.2 6.66 7.91 10.12
    Quick Ratio 6.37 7.89 11.2 4.42 2.03 2.23 2.24 3.95 6.31 7.62 9.8
    Debt/Equity 0.010